Product Pipeline Chart

Our CNS pipeline includes three differentiated CNS drug candidates with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of our drug candidates has a differentiated potential mechanism of action (or MOA), has been well-tolerated in all clinical studies to date, and has therapeutic potential in multiple CNS markets.